Otic Pharma appoints Greg Flesher to its Board of Directors as CEO

– ISRAEL, Rehovot / USA, CA – Otic Pharma Ltd, a privately held pharmaceutical company focused on developing innovative therapies for ear, nose, and throat disorders, today announced the appointment of Gregory J. Flesher as chief executive officer and member of the company’s board of directors.

Mr. Flesher brings more than 20 years of drug development and commercialization experience to Otic Pharma. Most recently he was chief business officer at Avanir Pharmaceuticals, Inc. until its acquisition by Otsuka Pharmaceutical for $3.5 billion earlier in the year. During his tenure at Avanir, Mr. Flesher had responsibility for leading the company’s corporate strategy, business development, investor relations, and corporate operations functions. Prior to Avanir, Mr. Flesher held positions at InterMune, Inc., Amgen Inc., and Eli Lilly and Company.

“We are extremely pleased to have Greg join the company,” said Erez Chimovits, managing director at OrbiMed and chairman of the board of directors for Otic Pharma. “Greg brings significant depth and breadth of leadership experience in the development and commercialization of new medicines. Under his leadership, he helped build Avanir from a small, single-product company into a leading neuroscience organization with a portfolio of products and more than 500 employees across the United States. Greg’s proven ability to successfully build organizations and create shareholder value made him the ideal candidate to lead Otic Pharma.”

About Otic Pharma

Otic Pharma, established in 2008, is a clinical-stage company active in the field of ear, nose, and throat disorders. The company’s current product candidates are based on FoamOtic, a proprietary foam-based drug delivery system that provides sustained exposure of drugs.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>